Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Bluebird Bio (BLUE -1.49%) stock got off to a roaring start on Monday, trouncing the S&P 500 index with a nearly 8% gain. The market was cheered by a clinical update and the potential for a new regulatory application in the near future.
On Saturday at a healthcare conference, Bluebird presented recent data on its gene therapies for beta-thalassemia and sickle cell disease (SCD).
The former, Zynteglo, produced transfusion independence for 41 participants in the 63-person set of phase 3 clinical trials. Beta thalassemia is an inherited blood disorder in which the body produces less hemoglobin than usual. Additionally, testimonials from three years after treatment indicate that 93% of those recipients were able to work, well above the 67% baseline. All participants reported overall improvement from the medication.
Zynteglo received Food and Drug Administration (FDA) approval in April. It was the first gene therapy green-lighted for beta-thalassemia patients requiring regular red blood cell transfusions.
Meanwhile, there was good news about the other (and related) Bluebird gene therapy that was a subject of the presentation. The biotech reported it is on track to submit lovo-cel, an investigational treatment that targets SCD, in the first quarter of next year for a Biologics License Application (BLA) from the FDA.
Despite some hiccups with lovo-cel (previously known as LentiGlobin), Bluebird has had quite a bit of success in 2022. It earned not one but two FDA approvals, that for Zynteglo plus a nod for Skysona, a treatment for neurological cerebral adrenoleukodystrophy. It seems the company is well positioned to keep that momentum going, particularly with the lovo-cel program steaming ahead.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Bluebird Bio. The Motley Fool has a disclosure policy.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
Making the world smarter, happier, and richer.
Market data powered by Xignite.
